Coronavirus disease 2019(COviD-19)was first reported three years ago,when a group of individuals were infected with the original SARS-CoV-2 strain,based on which vaccines were developed.Here,we develop six human monoc...Coronavirus disease 2019(COviD-19)was first reported three years ago,when a group of individuals were infected with the original SARS-CoV-2 strain,based on which vaccines were developed.Here,we develop six human monoclonal antibodies(mAbs)from two elite convalescents in Wuhan and show that these mAbs recognize diverse epitopes on the receptor binding domain(RBD)and can inhibit the infection of SARS-CoV-2 original strain and variants of concern(VOCs)to varying degrees,including Omicron strains XBB and XBB.展开更多
Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity,but it remains unclear how long it can maintain and how efficiently it can prevent the reinfection of the emerging SARS-CoV-2 variants.H...Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity,but it remains unclear how long it can maintain and how efficiently it can prevent the reinfection of the emerging SARS-CoV-2 variants.Here,we tested the sera from 248 COVID-19 convalescents around 1 year post-infection in Wuhan,the earliest known epicenter.SARS-CoV-2 immunoglobulin G(IgG)was well maintained in most patients and potently neutralizes the infection of the original strain and the B.1.1.7 variant.However,varying degrees of immune escape was observed on the other tested variants in a patient-specific manner,with individuals showing remarkably broad neutralization potency.The immune escape can be largely attributed to several critical spike mutations.These results suggest that SARS-CoV-2 can elicit long-lasting immunity but this is escaped by the emerging variants.展开更多
COVID-19 caused by SARS-CoV-2 infection has caused substantial morbidity and mortality worldwide and paralyzed the international economy.Understanding the magnitude and duration of the antibody response to SARS-CoV-2 ...COVID-19 caused by SARS-CoV-2 infection has caused substantial morbidity and mortality worldwide and paralyzed the international economy.Understanding the magnitude and duration of the antibody response to SARS-CoV-2 is important to achieve a balance between curbing the pandemic and minimizing adverse effects on society.1 Although the antibody response to SARS-CoV-2 within 9 months has been extensively studied,2,3,4,5,6 little is known about the magnitude and kinetics of antibody responses for over 9 months.Moreover,with limited observations over 9 months(n<100),2,7,8 several studies have produced inconsistent conclusions about antibody dynamics,suggesting different rates of antiviral antibody positivity at the last follow-up.2,7,8 These studies have been limited by a lack of measurement of neutralizing antibodies(NAbs),7 of inclusion of mild or asymptomatic cases,2,8 and of further exploration of potential predisposing factors for antibody dynamics.2,7 Considering the individual heterogeneity(such as disease severity)8 and time-dependent nature1 of the immune response,in-depth characterization of SARS-CoV-2 antibody kinetics across disease severity groups over a long period is urgently needed.Therefore,we repeatedly tested IgM,IgG,viral spike protein receptor-binding dom(anti-RBD)IgG,and NAb titers in COVID-19 patients during a follow-up period of up to 10 months and explored potential predisposing factors of antibody titers during follow-up.展开更多
基金This study was supported by the National Natural Science Foundation of China(32188101 to K.L.,32122008 to Y.W.,32270164 to H.Y.,and 32070160 to H.Y.)National Science and Technology Major Project(2022YFC2604100 to H.Z.and L.Z.,2021YFC2300702 to L.Z.,and 2021YFF0702004 to Y.C.)+2 种基金Fundamental Research Funds for the Central Universities(2042023kf0191 and 2042022kf1188 to H.Y.)Hubei Provincial Natural Science Foundation(2023AFA015 to H.Y.),China Postdoctoral Science Foundation(2023M732705 to Q.L.)Hubei Provincial Public Health Outstanding Young Talents Project(to K.C.).
文摘Coronavirus disease 2019(COviD-19)was first reported three years ago,when a group of individuals were infected with the original SARS-CoV-2 strain,based on which vaccines were developed.Here,we develop six human monoclonal antibodies(mAbs)from two elite convalescents in Wuhan and show that these mAbs recognize diverse epitopes on the receptor binding domain(RBD)and can inhibit the infection of SARS-CoV-2 original strain and variants of concern(VOCs)to varying degrees,including Omicron strains XBB and XBB.
基金supported by grants from the National Science and Technology Major Project(2018YFA0900801)China NSFC projects(32041007,32070160,and 82041004)+2 种基金Fundamental Research Funds for the Central Universities(2042021kf0220 and 2042020kf0024)the Advanced Customer Cultivation Project of Wuhan National Biosafety Laboratory(2021ACCP-MS10)Special Fund for COVID-19 Research of Wuhan University.
文摘Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity,but it remains unclear how long it can maintain and how efficiently it can prevent the reinfection of the emerging SARS-CoV-2 variants.Here,we tested the sera from 248 COVID-19 convalescents around 1 year post-infection in Wuhan,the earliest known epicenter.SARS-CoV-2 immunoglobulin G(IgG)was well maintained in most patients and potently neutralizes the infection of the original strain and the B.1.1.7 variant.However,varying degrees of immune escape was observed on the other tested variants in a patient-specific manner,with individuals showing remarkably broad neutralization potency.The immune escape can be largely attributed to several critical spike mutations.These results suggest that SARS-CoV-2 can elicit long-lasting immunity but this is escaped by the emerging variants.
基金supported by grants from the Fundamental Research Funds for the Central Universities(2019kfyXMBZ015)the 111 Project(Prof.Wu),the Fellowship of China Postdoctoral Science Foundation(2020T130034ZX,and 2020T130035ZX)+2 种基金the National Key Research and Development Plan Program of China(2020YFC0860800)the Revitalization Projects after the COVID-19 Plague of the China Association for Science and Technology(20200608CG111311)the Emergency Research Projects for COVID-19 Prevention and Control of the Wuhan Health Commission(EG20M01).
文摘COVID-19 caused by SARS-CoV-2 infection has caused substantial morbidity and mortality worldwide and paralyzed the international economy.Understanding the magnitude and duration of the antibody response to SARS-CoV-2 is important to achieve a balance between curbing the pandemic and minimizing adverse effects on society.1 Although the antibody response to SARS-CoV-2 within 9 months has been extensively studied,2,3,4,5,6 little is known about the magnitude and kinetics of antibody responses for over 9 months.Moreover,with limited observations over 9 months(n<100),2,7,8 several studies have produced inconsistent conclusions about antibody dynamics,suggesting different rates of antiviral antibody positivity at the last follow-up.2,7,8 These studies have been limited by a lack of measurement of neutralizing antibodies(NAbs),7 of inclusion of mild or asymptomatic cases,2,8 and of further exploration of potential predisposing factors for antibody dynamics.2,7 Considering the individual heterogeneity(such as disease severity)8 and time-dependent nature1 of the immune response,in-depth characterization of SARS-CoV-2 antibody kinetics across disease severity groups over a long period is urgently needed.Therefore,we repeatedly tested IgM,IgG,viral spike protein receptor-binding dom(anti-RBD)IgG,and NAb titers in COVID-19 patients during a follow-up period of up to 10 months and explored potential predisposing factors of antibody titers during follow-up.
